In a meta-analysis, both the 200-mg and 400-mg doses were effective, although the 400-mg dose was more effective in those with moderate-to-severe kidney disease.

The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in symptomatic adults 55 years and older.